Resistance in Hematologic Malignancies and Cancer
portes grátis
Resistance in Hematologic Malignancies and Cancer
Breier, Albert; Messingerova, Lucia
Elsevier Science Publishing Co Inc
11/2024
326
Dura
9780443217906
15 a 20 dias
Descrição não disponível.
1. Drug classification for treatment Hematological Malignancies
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
ABC transporters; Antibody-drug conjugate; Antitumor drugs; Apoptosis; Aryl hydrocarbon receptor; Autophagy; Cancer; Cancer chemoresistance; Cancer immunotherapy; Cell cycle; Cell death; Cell therapy; Chemoresistance; Chemotherapy; Chimeric antigen receptor T cell; Classification; Combination treatment; Cytotoxic payload; Diagnostics; Dormancy; Drug efflux; Drug influx; Drug resistance; Drug tolerance; Drug transporters; Endoplasmic reticulum; Genetic variants; Hematologic malignancies; Hematological malignancies; Hematological malignancy; Imaging; Immune checkpoint blockage; Immunomodulation; Immunotherapy; Leukemia; Mechanisms of resistance; Membrane barriers; Membrane fluidity and permeability; microRNAs; Multidrug resistance; Noncoding RNAs; Prognostics; Radiotherapy; Resistance; Resistance mechanisms; Solute carriers transporters; Strategies in management; Stress; Therapeutic strategies; Tumor microenvironment; Unfolded protein response; Xenobiotic-metabolizing enzymes
1. Drug classification for treatment Hematological Malignancies
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
ABC transporters; Antibody-drug conjugate; Antitumor drugs; Apoptosis; Aryl hydrocarbon receptor; Autophagy; Cancer; Cancer chemoresistance; Cancer immunotherapy; Cell cycle; Cell death; Cell therapy; Chemoresistance; Chemotherapy; Chimeric antigen receptor T cell; Classification; Combination treatment; Cytotoxic payload; Diagnostics; Dormancy; Drug efflux; Drug influx; Drug resistance; Drug tolerance; Drug transporters; Endoplasmic reticulum; Genetic variants; Hematologic malignancies; Hematological malignancies; Hematological malignancy; Imaging; Immune checkpoint blockage; Immunomodulation; Immunotherapy; Leukemia; Mechanisms of resistance; Membrane barriers; Membrane fluidity and permeability; microRNAs; Multidrug resistance; Noncoding RNAs; Prognostics; Radiotherapy; Resistance; Resistance mechanisms; Solute carriers transporters; Strategies in management; Stress; Therapeutic strategies; Tumor microenvironment; Unfolded protein response; Xenobiotic-metabolizing enzymes
